Buyer clubs and executive access for Series A companies: the 90-day install for healthcare and life sciences in North America
The exact 90-day plan for standing up buyer clubs and executive access at Series A — the point where the founder can no longer be every function. Written for commercial leaders at healthtech, medtech, and life-sciences companies in North America.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in North America. In this market, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed, so the way you install buyer clubs and executive access has to be shaped to that reality from day one.
Series A is the moment buyer clubs and executive access stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire cycle length from first touch to closed-won into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in North America it is compounded by the fact that signal above noise, not lead volume is what actually gates growth. Buyer clubs and executive access is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: confusing sponsorship with membership. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of buyer clubs and executive access looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for healthcare and life sciences in North America: the healthcare teams that install this get past procurement instead of dying in it, and the North American teams that install this land inside the first quarter, not the fourth. That is the reason it is worth installing buyer clubs and executive access deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Buyer Access · healthcare · North America — answered
- Does buyer clubs and executive access work for healthcare and life sciences in North America?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in North America, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed. The healthcare teams that install this get past procurement instead of dying in it.
- Should we start buyer clubs and executive access before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund buyer clubs and executive access?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first buyer clubs and executive access operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Confusing sponsorship with membership — usually a premature senior hire.
- What is the North America-specific pitfall when running buyer clubs and executive access for healthcare?
- Importing a playbook that was built for another market. In North America, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed — the install has to reflect that.
Growth Broker editorial
Filed under buyer access · healthcare · north america